• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Merus N.V. (Amendment)

    2/14/24 4:05:33 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Merus N.V.

     

    (Name of Issuer)

     

    Common shares, €0.09 nominal value per share

     

    (Title of Class of Securities)

     

    N5749R100

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. N5749R100 SCHEDULE 13G  

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,747,373*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,747,373*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,747,373*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.2%*

    12

    TYPE OF REPORTING PERSON

     

    IA

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. N5749R100 SCHEDULE 13G  

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,747,373*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,747,373*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,747,373*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.2%*

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. N5749R100 SCHEDULE 13G  

     

    Item 1. (a) Name of Issuer

     

    Merus N.V. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    Uppsalalaan 17, 3584 CT Utrecht, The Netherlands

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common shares, €0.09 nominal value per share (the “Common Stock”)

     

    Item 2. (e) CUSIP No.:

     

    N5749R100

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. N5749R100 SCHEDULE 13G  

     

    Item 4.Ownership

     

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

     

    (a) Amount Beneficially Owned: 4,747,373*

     

    (b) Percent of Class: 8.2%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 4,747,373*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 4,747,373*

     

      As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

    (a) Amount Beneficially Owned: 4,747,373*

     

    (b) Percent of Class: 8.2%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 4,747,373*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 4,747,373*

     

    *The Firm is the investment manager to Commodore Master. As of December 31, 2023, the Firm may be deemed to beneficially own an aggregate of 4,747,373 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 57,732,814 shares of Common Stock reported as issued and outstanding as of October 30, 2023 in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class
      
     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

     

     

     

    CUSIP No. N5749R100 SCHEDULE 13G  

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10.Certification
      
     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

      1.Joint Filing Agreement dated as of May 16, 2022, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on May 16, 2022).

     

     

     

     

    CUSIP No. N5749R100 SCHEDULE 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Commodore Capital LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
         
    Commodore Capital Master LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

     

     

     

    Get the next $MRUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    11/2/2023$45.00Buy
    Canaccord Genuity
    8/21/2023Outperform
    TD Cowen
    More analyst ratings

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO & PEO Lundberg Sven Ante exercised 30,297 shares at a strike of $13.40 (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      4/21/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 3,000 shares and sold $193,990 worth of shares (4,000 units at $48.50), decreasing direct ownership by 8% to 11,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:10:05 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 5,000 shares, increasing direct ownership by 71% to 12,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merus to Present at BofA Securities 2025 Health Care Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. About MerusMerus is an oncology company de

      5/8/25 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merus N.V.

      10-Q - Merus N.V. (0001651311) (Filer)

      5/7/25 4:05:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Merus N.V.

      DEF 14A - Merus N.V. (0001651311) (Filer)

      4/24/25 4:05:39 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Merus N.V.

      PRE 14A - Merus N.V. (0001651311) (Filer)

      4/14/25 4:15:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Financials

    Live finance-specific insights

    See more
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

      -  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

      2/27/25 4:10:40 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Merus with a new price target

      Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

      2/13/25 8:09:56 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Merus with a new price target

      Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00

      2/7/25 8:26:14 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Merus with a new price target

      Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00

      11/21/24 7:35:31 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 6, 2024 - FDA Roundup: December 6, 2024

      For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

      12/6/24 3:09:02 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 4:05:20 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 1:34:01 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 8:54:46 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

      7/1/24 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

      6/15/23 7:47:06 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

      1/25/22 4:30:00 PM ET
      $INCY
      $MRUS
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations